Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Pending | |||
| TBC | momelotinib | Myelofibrosis | Pending | |||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended |
Last Updated : May 16, 2024